Floatz logo

DEXAMETHASONE

Relapsed/Refractory

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
81/ 100

Competitive context

15 Active assets in the Relapsed/Refractory cohort.

Asset / SponsorPhaseRating
Bcma Car-T Cells
The First Affiliated Hospital of Xiamen University
Phase 2CCC
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
University Health Network, Toronto
Phase 2CCC
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 1/2CCC
Pomalidomide
Millennium Pharmaceuticals, Inc.
Phase 1/2CCC
Mezagitamab
Millennium Pharmaceuticals, Inc.
Phase 1/2CCC

View all 18 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →